SRPT

Sarepta Therapeutics, Inc.

117.23 USD
+1.61 (+1.39%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Sarepta Therapeutics, Inc. stock is down -8.37% since 30 days ago. The next earnings date is May 3, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 11 April’s closed higher than March. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Apr 16:10 17 May, 2024 135.00 CALL 220 471
19 Apr 16:17 19 Jul, 2024 100.00 CALL 50 2312
19 Apr 16:18 19 Jul, 2024 100.00 CALL 50 2312
19 Apr 16:18 19 Jul, 2024 100.00 CALL 50 2312
19 Apr 16:18 19 Jul, 2024 100.00 CALL 50 2312
19 Apr 18:42 19 Jul, 2024 100.00 CALL 50 2312
19 Apr 18:43 19 Jul, 2024 100.00 CALL 25 2312
19 Apr 18:43 19 Jul, 2024 100.00 CALL 25 2312
19 Apr 18:43 19 Jul, 2024 100.00 CALL 25 2312
22 Apr 15:50 15 Aug, 2025 120.00 CALL 9 156

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.